Ensign Peak Advisors, Inc Sage Therapeutics, Inc. Transaction History
Ensign Peak Advisors, Inc
- $55.3 Billion
- Q4 2024
A detailed history of Ensign Peak Advisors, Inc transactions in Sage Therapeutics, Inc. stock. As of the latest transaction made, Ensign Peak Advisors, Inc holds 44,021 shares of SAGE stock, worth $314,309. This represents 0.0% of its overall portfolio holdings.
Number of Shares
44,021
Previous 42,721
3.04%
Holding current value
$314,309
Previous $308,000
22.4%
% of portfolio
0.0%
Previous 0.0%
Shares
13 transactions
Others Institutions Holding SAGE
# of Institutions
189Shares Held
42MCall Options Held
301KPut Options Held
157K-
Black Rock Inc. New York, NY5.22MShares$37.2 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.84MShares$34.5 Million0.0% of portfolio
-
Morgan Stanley New York, NY4.59MShares$32.8 Million0.0% of portfolio
-
Bellevue Group Ag Kuesnacht, V84.46MShares$31.8 Million0.48% of portfolio
-
Rtw Investments, LP New York, NY3MShares$21.4 Million0.27% of portfolio
About Sage Therapeutics, Inc.
- Ticker SAGE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,422,300
- Market Cap $424M
- Description
- Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...